AUTHOR=Bansal Pranshu , Osman Diaa , Gan Gregory N. , Simon George R. , Boumber Yanis 

TITLE=Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC

JOURNAL=Frontiers in Oncology

VOLUME=6

YEAR=2016

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2016.00112

DOI=10.3389/fonc.2016.00112

ISSN=2234-943X

ABSTRACT=<p>Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (<italic>EGFR</italic>) mutations, anaplastic lymphoma kinase (<italic>ALK</italic>) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against oncogenic targets, including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET, and NTRK. With the rapidly evolving molecular testing and development of new targeted agents, our ability to further personalize therapy in non-squamous NSCLC is rapidly expanding.</p>